Fatima Zahra Bellefkih
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fatima Zahra Bellefkih has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Bennassi
AP-HP. Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, 1 rue Gustave Eiffel, 94000 Créteil, France
2 shared publications Nisrine El Hayel
Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, APHP, UPEC, Créteil, France
2 shared publicationsAnna Durigova
Department of Oncology, Rte du Vieux Séquoia 20, 1847 Rennaz, Switzerland
1 shared publicationCéline Droumaguet
Department of Internal Medicine, Henri Mondor Hospital, 1 rue Gustave Eiffel, 94000 Créteil, France
1 shared publication- Dusanka Tesanovic
Radiotherapy Department, Institute for Oncology of Vojvodina, Sremska Kamenica, Serbia
1 shared publication Dusanka Tešanović
Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
1 shared publication
Latest Publications
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (7) , e2500498
Concurrent New Systemic Therapies and Radiation Therapy in Breast Cancer: Current Evidence, Future Challenges, and Expert Practice Recommendations for Low- and Middle-Income Countries
PURPOSE: The integration of novel systemic therapies including antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with radiotherapy (RT) presents new opportunities in breast cancer (BC) management. However, clinical guidance on concurrent administration remains limited, particularly for advanced techniques. MATERIALS AND METHODS: A multidisciplinary panel of radiation and medical oncologists from AROME and the Moroccan Medical Oncology Association conducted a literature review and established expert consensus recommendations during the fourth Moroccan Congress of Medical Oncology Private Practice. An evidence-informed, structured consensus process was used to achieve agreement on safety profiles across six RT modalities. RESULTS: Trastuzumab deruxtecan has shown a favorable safety profile with whole-breast irradiation and palliative RT, while trastuzumab emtansine combined with stereotactic radiosurgery shows elevated radionecrosis risk. ICIs are generally feasible with most RT modalities and toxicity monitoring applied; however, risk is context dependent, and evidence supporting stereotactic body radiotherapy-ICI benefit in oligometastatic BC remains limited. The use of CDK4/6 inhibitors concurrently with conventional and stereotactic RT seems feasible, although caution is advised for visceral metastases. These experts' agreements are supported by retrospective data and preclinical evidence, highlighting the need for prospective validation. CONCLUSION: This expert consensus statement provides pragmatic, modality-specific guidance on combining contemporary RT techniques with selected novel systemic agents in BC, complementing existing European Society for Medical Oncology /European Society for Radiotherapy and Oncology‑oriented frameworks and highlighting areas where prospective data are still needed. The findings underscore the importance of toxicity monitoring, particularly for ADCs in CNS-directed therapies, and call for biomarker-driven studies to optimize combination strategies. These recommendations aim to guide safe integration of novel agents with RT across resource-variable settings, including low- and middle-income countries.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (7) , e2500498
Concurrent New Systemic Therapies and Radiation Therapy in Breast Cancer: Current Evidence, Future Challenges, and Expert Practice Recommendations for Low- and Middle-Income Countries
PURPOSE: The integration of novel systemic therapies including antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with radiotherapy (RT) presents new opportunities in breast cancer (BC) management. However, clinical guidance on concurrent administration remains limited, particularly for advanced techniques. MATERIALS AND METHODS: A multidisciplinary panel of radiation and medical oncologists from AROME and the Moroccan Medical Oncology Association conducted a literature review and established expert consensus recommendations during the fourth Moroccan Congress of Medical Oncology Private Practice. An evidence-informed, structured consensus process was used to achieve agreement on safety profiles across six RT modalities. RESULTS: Trastuzumab deruxtecan has shown a favorable safety profile with whole-breast irradiation and palliative RT, while trastuzumab emtansine combined with stereotactic radiosurgery shows elevated radionecrosis risk. ICIs are generally feasible with most RT modalities and toxicity monitoring applied; however, risk is context dependent, and evidence supporting stereotactic body radiotherapy-ICI benefit in oligometastatic BC remains limited. The use of CDK4/6 inhibitors concurrently with conventional and stereotactic RT seems feasible, although caution is advised for visceral metastases. These experts' agreements are supported by retrospective data and preclinical evidence, highlighting the need for prospective validation. CONCLUSION: This expert consensus statement provides pragmatic, modality-specific guidance on combining contemporary RT techniques with selected novel systemic agents in BC, complementing existing European Society for Medical Oncology /European Society for Radiotherapy and Oncology‑oriented frameworks and highlighting areas where prospective data are still needed. The findings underscore the importance of toxicity monitoring, particularly for ADCs in CNS-directed therapies, and call for biomarker-driven studies to optimize combination strategies. These recommendations aim to guide safe integration of novel agents with RT across resource-variable settings, including low- and middle-income countries.
- Open Access
- 25 May 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101195
Primary adrenal insufficiency in patients with bilateral adrenal metastases treated with curative ablative radiation therapy: A comprehensive review of literature and expert agreements for radiation practice
- 25 May 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101195
Open AccessPrimary adrenal insufficiency in patients with bilateral adrenal metastases treated with curative ablative radiation therapy: A comprehensive review of literature and expert agreements for radiation practice
- 3 February 2024
- Published by Elsevier in Brachytherapy
- Vol. 23 (2) , 154-164
Patterns of practice survey for cervical cancer brachytherapy in Morocco
- 3 February 2024
- Published by Elsevier in Brachytherapy
- Vol. 23 (2) , 154-164
Patterns of practice survey for cervical cancer brachytherapy in Morocco